Find out the latest news about NextCell

ProTrans stem cells approved for clinical trials in COVID-19 patients

NextCell Pharma AB ("NextCell") today announces that the application for clinical trial of COVID-19 patients with the drug candidate ProTrans has been approved by both the Ethics Committy and the Swedish Medical Product Agency. The study will be conducted at the University Hospital in Örebro in c...
Read more

NextCell presents at “Investerarjakten”

NextCell Pharma AB (“NextCell”) will today at 15:00 present at Investerarjakten. Viewers have the possibility to ask questions directly to CEO Mathias Svahn. The event is broadcast live on Studio Direct's youtube channel, the facebook group Aktier and on Investerarbrevet.se between 13:00-17:00. ...
Read more

Presentation of the positive results from ProTrans-2

NextCell Pharma AB ("NextCell") announced earlier this week that the clinical diabetes trial ProTrans-2 had met the primary endpoints. On the occation of that, the principal investigator Professor Per-Ola Carlsson together with NextCell will hold a webcast presentation today, Thursday 10 Septembe...
Read more

ProTrans shows significant effect in Diabetes

NextCell Pharma AB ("NextCell") today announces that the ProTrans-2 clinical trial met the primary endpoint. Patients treated with a single dose ProTrans show a statistically significant improved preservation of insulin production over 12 months, compared to patients treated with placebo (p-value...
Read more
NextCell announces Eurostars grant for developing an innovative cell therapy production platform
NextCell Pharma AB (“NextCell” or the “Company”) announces today that the Company together with 3 partner organizations have been awarded a €1.6M Eurostars grant of which NextCell’s share is €470,000. The aim of the project entitled Bioscale, is to optimise automated bioreactors to manufacture th...
Read more
NextCell Pharma AB publishes its interim report for September 2019 - May 2020
NextCell Pharma AB (publ) (NXTCL) today announces that its Interim report for the period September 1, 2019 - May 31, 2020 now is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report Nine months (2019-09-01 until 2020-05-31) · Operating income amounted...
Read more
NextCell approved for trading on Nasdaq First North
NextCell Pharma AB (publ) (“NextCell” or “the Company”) announces that Nasdaq Stockholm AB today has approved their application for trading on Nasdaq Stockholm First North. The last day for trading on Spotlight is Tuesday, July 21, 2020 and the first day for trading on Nasdaq First North is Wedne...
Read more
NextCell Pharma AB’s rights issue heavily oversubscribed
The Board of Directors of NextCell Pharma AB ("NextCell" or the “Company”) announces today the outcome in the Company’s new issue of shares with preferential rights for existing shareholders (the “Rights Issue”). The demand was high and the Rights Issue was oversubscribed. Thus, no guarantees hav...
Read more
NextCell's phase II study is completed – a phase III is being prepared
NextCell Pharma AB ("NextCell") announces that the last patient now has left ProTrans-2, meaning the phase II trial with the drug candidate ProTrans for treatment of type 1 diabetes, is completed according to plan. Data will be compiled and analyzed by independent statistician to be presented dur...
Read more
NextCell Pharma AB publishes prospectus relating to the rights issue and announces the intention of change of listing to Nasdaq First North in July
The Board of Directors of NextCell Pharma AB ("NextCell" or the “Company”) has prepared a prospectus (the “Prospectus”) relating to the new issue of shares with preferential rights for existing shareholders of approximately SEK 25.1 million (the Rights Issue”), which was resolved by the Board of ...
Read more
Invited to panel discussion; Post-Covid-19 world
NextCell Pharma AB ("NextCell") has been invited to participate in the panel discussion entitled “The impact of corona virus on the global healthcare - new challenges and main problems”. Doctor Lindsay Davies, Chief Scientific Officer at NextCell and researcher at Karolinska Institutet will join ...
Read more
The Board of Directors of NextCell Pharma AB resolves on a fully guaranteed SEK 25.1 million rights issue
NextCell Pharma AB ("NextCell" or the “Company”) announces that the Board of NextCell Pharma AB has resolved to conduct a fully guaranteed new issue of shares of approximately SEK 25.1 million with preferential rights for the Company's existing shareholders (the "Rights Issue"), subject to approv...
Read more


Interview with the CEO in Biostock
NextCell Pharma wants to rethink the treatment paradigm for diabetes.
Read more
Article about NextCell Pharma in Biostock
NextCell Pharma will pass several milestones via share issue
Read more
Interview with NextCell Pharma's CEO Mathias Svahn
Our fully recruited Phase 2-study is almost finished and we see no risk for delays despite the current pandemic. The results are as expected for Q3.
Read more
The stem cell treatment that could stop diabetes
Diabetes is increasing among children and young people. Today the disease is incurable, but the stem cell company NextCell Pharma believes that diabetes and several other diseases could be treated with stem cells.
Read more

Company Presentations

Ladda ner

Expert Event

Independent diabetes and cell therapy experts comment on data published.
Ladda ner

News announcement

NextCell Pharma - ProTrans shows significant effect in diabetes
Ladda ner

Aktiespararnas aktiedag, 2020-05-04

CEO Mathias Svahn presents the company (in Swedish)
Ladda ner

Elevator Pitch

A short video where CEO Mathias Svahn introduces the company

Company Analyses

Analyst Group
Bull & Bear-Analysis
New capital enables completion of Phase I/II
Read more
SvD Näringsliv
Nextcell Pharma: A rare investment opportunity
The stem cell company NextCell is currently issuing new shares to finance the ongoing development of their drug candidate ProTrans. (Article in Swedish)
Read more
Analyst Group
Bull & Bear-Analysis
Unique stem cell company with potential within several diseases
Read more